AstraZeneca, Breast Cancer and Datroway
FDA Approves AstraZeneca's Datroway For Pretreated Breast Cancer Patients
On Friday, the U.S. Food and Drug Administration (FDA) approved AstraZeneca Plc’s (NASDAQ:AZN) Datroway (datopotamab deruxtecan or Dato-DXd) for adult patients with unresectable or metastatic hormone receptor (HR)-positive,
The clearance of Datroway comes months after the companies narrowed approval plans in lung cancer and opens up a market ...
Even before the FDA's recent approval of Dato-DXd in breast cancer, analysts predicted sales of the antibody-drug conjugate ...
AstraZeneca PLC AZN shares rallied 2.39% to £110.52 Tuesday, on what proved to be an all-around great trading session for the stock market, with the FTSE 100 Index UKX rising 0.33% to 8,548.29.
AstraZeneca has overhauled its local management in China, replacing Michael Lai with Alex Lin as the country's general ...
DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.
Shares of AstraZeneca PLC AZN slid 1.32% to £107.94 Monday, on what proved to be an all-around great trading session for the ...
Goldman Sachs analyst Rajan Sharma maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of £155.58. The ...
AstraZeneca’s share price has fallen a long way from its record-breaking level last year, which indicates that I may be ...
From accelerating drug development and clinical trials to supercharging collaboration, machine learning-enhanced healthcare ...
President Trump rescinded an executive order that prompted the creation of three Medicare drug-pricing experiments ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback